TrialLineage
Concept pages
TrialLineage lineages trace the full scientific path behind a clinical trial — from basic discovery through chemistry, biology, and translation into human testing. Concept pages explain the individual scientific fields and ideas that appear along that lineage, in plain language and with the same editorial care.
About these pages
Why concept pages exist
A clinical trial does not emerge from a single discovery. It is the product of many fields — genetics, cell biology, chemistry, pharmacology, clinical medicine — each contributing ideas, tools, and evidence over decades. Concept pages provide plain-language background on these fields, covering the full context behind a TrialLineage history, including the branch points in scientific thinking, the failed approaches that still taught the field something, and the ideas that had to exist before a trial became possible.
Each concept page is written to be read independently or as a companion to a lineage page. They are designed for a public audience — not as textbook chapters, but as serious, accessible explanations of the science behind human-disease trials.
Browse concepts
All concept pages
Oncogene discovery
How the identification of cancer-causing genes changed the way scientists understood the disease — and why it was the starting point for targeted therapies.
Read explainer →
Protein signaling biology
The science of how proteins relay messages inside cells, and why disruptions in these relay chains drive cancer growth.
Read explainer →
Clinical trial design
What phase 1, 2, and 3 trials actually test, why trial design is part of the discovery process, and how design choices shape what we learn about a drug.
Read explainer →
Medicinal chemistry
The discipline of designing molecules that can act as drugs — bridging biological insight to a compound that can be tested in humans.
Read explainer →
Translational oncology
How laboratory discoveries about cancer are converted into clinical hypotheses, preclinical evidence, and eventually human trials.
Read explainer →
Structural biology
The study of the three-dimensional shapes of proteins and other biological molecules, and why those shapes determine what drugs can do.
Read explainer →
Chemical biology
Using small molecules as tools to probe biological questions — testing whether a protein can be chemically engaged and what happens when it is.
Read explainer →
Pancreatic precursor lesion biology
The science of how pancreatic cancer develops from earlier, pre-cancerous changes — and why understanding those stages matters for early detection and treatment.
Read explainer →
Gene therapy
A medical approach that treats disease by delivering genetic material into a patient's cells, addressing the underlying cause rather than managing symptoms.
Read explainer →
Viral vectors / AAV
Engineered viruses stripped of pathogenicity and repurposed to deliver therapeutic genes into human cells — the delivery mechanism behind retinal gene therapy.
Read explainer →
Inherited retinal disease
A group of genetic conditions that damage the cells responsible for vision, now understood as targets for gene-specific therapies.
Read explainer →
Molecular diagnosis
Identifying the specific genetic mutation responsible for a patient's disease — the gatekeeping step that determines eligibility for gene therapy.
Read explainer →
Retinal biology
The cellular architecture of the retina — photoreceptors, pigment epithelium, and supporting layers — and why it matters for understanding vision loss and gene therapy targets.
Read explainer →
Rare disease trials
How clinical trials are designed for diseases with small patient populations, variable progression, and novel endpoints.
Read explainer →
Translational medicine
The process of moving discoveries from basic science into clinical practice — bridging laboratory findings and patient benefit.
Read explainer →
RNA biology
The molecular intermediary between DNA and protein — and the foundation for RNA-targeted therapies including antisense oligonucleotides and siRNAs.
Read explainer →
Gene expression
The process by which information encoded in DNA is converted into functional products. When expression regulation fails, disease can result.
Read explainer →
Antisense oligonucleotides
Short synthetic nucleic acids designed to bind specific RNA sequences — enabling degradation, blocking, or splicing modulation of target transcripts.
Read explainer →
Angelman syndrome
A rare neurodevelopmental genetic disorder caused by loss of neuronal UBE3A expression, now a target for RNA-based therapeutic strategies.
Read explainer →
UBE3A
An E3 ubiquitin ligase gene subject to brain-specific imprinting — the molecular target in Angelman syndrome and the basis for ASO-mediated unsilencing strategies.
Read explainer →
Rare genetic disease
Conditions caused by heritable DNA changes affecting small populations — often the proving grounds for precision genetic therapies.
Read explainer →
CNS drug delivery
Strategies for getting therapeutic molecules past the blood-brain barrier and into neural tissue — a critical enabling step for neurological gene therapies.
Read explainer →
More to come
TrialLineage is building concept pages for each scientific field that appears in the discovery lineage behind a clinical trial. New pages will be added as the platform expands to cover additional lineages and the scientific areas they depend on. If a concept is listed above but not yet linked, it is in preparation.